BioMarin Pharma (BMRN) Tops Q4 EPS by 12c

Go back to BioMarin Pharma (BMRN) Tops Q4 EPS by 12c

PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)

February 23, 2015 12:28 PM EST

PTC Therapeutics (NASDAQ: PTCT) is paring some gains related to M&A speculation. One noted biotech watcher thinks a move for BioMarin (Nasdaq: BMRN) to acquire PTCT is unlikely.

$BMRN is interested in buying $PTCT? Thats hard to believe.

— Adam Feuerstein (@adamfeuerstein) February 23, 2015
... More

UPDATE: PTC Therapeutics (PTCT) pops; said to be exploring possible sale - Reuters

February 23, 2015 12:03 PM EST

(Updated - February 23, 2015 12:43 PM EST)

PTC Therapeutics (NASDAQ: PTCT) pops on chatter the company is exploring a sale, according to Reuters headlines.

According to the report, the company has received takeover interest from several pharmaceutical companies including Shire plc (NASDAQ:... More

BioMarin Pharma (BMRN) Announces Granting of 91.6k RSUs

February 23, 2015 6:52 AM EST

BioMarin Pharma (NASDAQ: BMRN) announced that on February 17, 2015, the compensation committee of BioMarin's board of directors approved the grant to 125 newly hired employees of 91,610 restricted share units in the aggregate and stock options to purchase 35,400 shares of common stock in the aggregate. A portion of these grants are special inducement grants to certain employees of... More